Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
liver cancer
Pharma
Merck's Keytruda-Lenvima combo triumphs in liver cancer subtype
The positive intermediate-stage liver cancer readout comes after the Keytruda-Lenvima combo failed to beat Lenvima alone in advanced liver cancer.
Angus Liu
Sep 14, 2024 10:30am
UPDATED: Elevar, Hengrui eye accelerated refile for PD-1 combo
Jul 12, 2024 12:08am
Junshi, Coherus move Loqtorzi closer to another approval
Jun 12, 2024 11:45am
ASCO: Bristol calls Roche and AZ's bets in 1L liver cancer
Jun 4, 2024 8:00am
FDA rejects Elevar, Hengrui's PD-1 combo
May 17, 2024 10:16am
BMS shoots for 1L liver cancer again with Opdivo, Yervoy combo
Mar 20, 2024 10:18am
